Evaluation of Crestor® (Rosuvastatin) in Daily Practice

Open-Label Non-Interventional Evaluation of Efficacy of Crestor® (Rosuvastatin) in Reduction of LDL-Cholesterol and Cardiovascular Risk Parameters in Patients With Hypercholesterolaemia

This open label, non-interventional study is to show the efficacy of Crestor (rosuvastatin) in reduction of LDL-cholesterol and cardiovascular risk parameters in patients with hypercholesterolemia. Effectiveness is to be evaluated using the difference in LDL cholesterol level between the first and the second visit after 12 weeks.

Inclusion Criteria:

• a patient with hypercholesterolemia who has been prescribed Crestoraccording to physician's judgement, irrespective of the inclusion in the study.
• no treatment with any statin in the last 3 months

Exclusion Criteria:

• hypersensitivity to rosuvastatin or any other ingredient of Crestor
• active liver disease, severe renal insufficiency
• myopathy or predisposing risk factors for myopathy/ rhabdomyolysis
• woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation